论文部分内容阅读
自1971年7月～1982年12月应用秋水仙硷制剂和CU方案围手术辅助治疗乳腺癌420例。总的10年以上生存率为56％，其中有效组（CR＋PR）与无效组（SD＋PD）分别为71％及48．6％（P＝0．00001）。肿瘤对本前化疗药物越敏感预后越好，其中CR组经病理证实腋淋巴结转移率仅30％，局部欠发率为5％，10年以上生存率达到了85％。作者认为乳腺癌的因手术辅助化疗，尤其是术前有效药物的化疗对改善预后有较好的效果。
From July 1971 to December 1982, 420 cases of breast cancer were treated with colchicine preparation and CU regimen. The overall 10-year survival rate was 56%, of which the effective group (CR+PR) and ineffective group (SD+PD) were 71% and 48.6%, respectively (P=0.00001). The more sensitive the tumor to the previous chemotherapeutic drugs, the better the prognosis. Among the CR patients, pathologically confirmed axillary lymph node metastasis rate was only 30%, the local under-running rate was 5%, and the 10-year survival rate reached 85%. The authors believe that surgical adjuvant chemotherapy for breast cancer, especially preoperative chemotherapy, has a good effect on improving prognosis.